About Sunovion
Sunovion is a company based in Marlborough (United States) founded in 1984 was acquired by Sumitomo Dainippon Pharma in August 2021. Sunovion has completed 2 acquisitions, including Cynapsus Therapeutics and Elevation Pharmaceuticals. Sunovion offers products and services including Drug Pipeline and Cell and Gene Therapies.
- Headquarter Marlborough, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sumitomo Pharma America, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Investments & Acquisitions
Cynapsus Therapeutics
& 1 more
-
Acquired by
Sumitomo Dainippon Pharma
(Aug 19, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sunovion
Sunovion offers a comprehensive portfolio of products and services, including Drug Pipeline and Cell and Gene Therapies.
Advances drugs for oncology and rare diseases through clinical trials
Develops treatments for genetic and rare conditions
People of Sunovion
Unlock access to complete
Funding Insights of Sunovion
Detailed funding history for Sunovion
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Sunovion
Sunovion has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Sumitomo Dainippon Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceuticals, food ingredients, additives, and veterinary products are manufactured.
|
Locked | Locked | Locked |
Investor details for Sunovion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sunovion
Sunovion has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Cynapsus Therapeutics and Elevation Pharmaceuticals.
Investment portfolio details for Sunovion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of aerosol drug products for COPD patients
|
Locked | Locked | 2007 | Locked | |
|
Treatments for CNS disorders, including Parkinson's OFF episodes, are developed.
|
Locked | Locked | 2004 | Locked |
Complete acquisition details for Sunovion
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Sunovion
Detailed financials for Sunovion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sunovion Comparisons
Peer comparison for Sunovion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sunovion
Detailed competitors of Sunovion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sunovion
Complete news archive for Sunovion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sunovion
Sunovion was founded in 1984.
Sunovion is headquartered in Marlborough, United States. It is registered at Marlborough, Massachusetts, United States.
Sunovion engages in discovering, developing, and commercializing therapeutic products for patients suffering from central nervous system disorders, respiratory disorders and other illnesses. Products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Zetonna (ciclesonide) Nasal Aerosol, and Alvesco (ciclesonide) Inhalation Aerosol. Pipeline includes latuda for pediatric schizophrenia, SUN-101 for COPD, dasotraline for ADHD and binge eating disorder, SB-623 for chronic stroke, SEP-856 for schizophrenia, DSP-2230 for neuropathic pain, DSP-3748 for cognitive impairment associated with schizophrenia and WT-2725 for hematologic and solid cancer.
Sunovion offers Drug Pipeline and Cell and Gene Therapies.
Sunovion has made 2 acquisitions, including Cynapsus Therapeutics, and Elevation Pharmaceuticals.
Sunovion has 1 investor. Key investors include Sumitomo Dainippon Pharma.